Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Recently approved IOP-lowering prostaglandin highlighted at Prague glaucoma meeting

March 29, 2001

ROCK inhibitors investigated for potential as antiglaucoma drugs

March 29, 2001

Expanded use of Visudyne approved in E.U.

March 27, 2001

Iomed and Santen to develop treatment of posterior eye diseases

March 26, 2001

Two new antiglaucoma drugs approved by FDA

March 19, 2001

Six-month trial results show Lumigan clinically superior to timolol in lowering IOP

March 6, 2001

Japanese patent issued to Santen for new agents for glaucoma

March 1, 2001

Statistically significant phase II results reported for INS-365 Ophthalmic

Feb. 28, 2001

Santen granted rights to develop and market lomerizine for ophthalmological indications

Feb. 27, 2001

Promising data reported for Visudyne in occult AMD and pathological myopia

Feb. 14, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...